NasdaqCM:VRDNBiotechs
Why Viridian Therapeutics (VRDN) Is Up 31.8% After Positive Phase 3 Eye Drug Data and New Financing
Viridian Therapeutics recently reported first-quarter 2026 results showing modest revenue of US$141,000 alongside a wider net loss of US$104.9 million, while also launching US$150 million in convertible notes due 2032 and filing a US$100 million follow-on equity offering.
At the same time, Viridian released positive Phase 3 REVEAL-2 data for elegrobart in chronic thyroid eye disease and prepared for potential commercialization of veligrotug, signaling a possible shift toward becoming a...